{"id":"1dab2be8-f826-5101-8b8d-44be8611e109","stable_key":"6660bba2-4fa0-590a-bf52-9803a24bea9f:ss-ce-158-kinetics","predicate":"reported_relationship","statement":"ss-ce-158 was among the more slowly dissociating modafinil analogues in the 2026 DAT-current-recovery experiments; plasma persistence and target residence are separate.","claim_class":"mechanistic","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"15c6660c-3605-50a0-b69e-787a2904ee50","mechanism_event_label":"ss-ce-158 was among the more slowly dissociating modafinil analogues in the 2026 DAT-current-recovery experiments; plasma persistence and target residence are separate.","subject":{"id":"78e15daa-d80d-5c39-9fc4-724d09669a68","slug":"ss-ce-158","display_name":"(S,S)-CE-158 modafinil analogue","entity_type_key":"small_molecule"},"object":{"id":"9e5c68df-f041-565a-8c77-b1282ff645eb","slug":"slc6a3","display_name":"Human dopamine transporter / DAT / SLC6A3","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"15c6660c-3605-50a0-b69e-787a2904ee50","stable_key":"6660bba2-4fa0-590a-bf52-9803a24bea9f:ss-ce-158-kinetics-event","event_type":"biochemical_relationship","label":"ss-ce-158 was among the more slowly dissociating modafinil analogues in the 2026 DAT-current-recovery experiments; plasma persistence and target residence are separate.","description":"**A 2026 update adds actual binding-kinetic experiments.** Investigators measured DAT-current recovery after inhibitor removal, compared R-modafinil with analogues, and studied dopamine dynamics and cognition in rats. More slowly dissociating analogues such as S-MK-26 and (S,S)-CE-158 performed better on selected outcomes, including tasks impaired by scopolamine. Brain exposure also differed. The findings support investigating residence time, but do not isolate it from every pharmacokinetic difference or show that marketed modafinil has no abuse liability. Findings from these analogues belong to their own records. [Niello et al., 2026](https://doi.org/10.1016/j.neuropharm.2026.110969)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"78e15daa-d80d-5c39-9fc4-724d09669a68","slug":"ss-ce-158","display_name":"(S,S)-CE-158 modafinil analogue","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"9e5c68df-f041-565a-8c77-b1282ff645eb","slug":"slc6a3","display_name":"Human dopamine transporter / DAT / SLC6A3","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""},{"entity":{"id":"a61c79bf-b0f9-5c6e-a465-2e210f77a5ac","slug":"armodafinil","display_name":"Armodafinil / R-modafinil","entity_type_key":"drug"},"role":"comparative compound","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract and publisher experimental procedures, results and discussion inspected; no supplementary-data reanalysis.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"DAT-current recovery after inhibitor removal; transporter construct details remain in primary paper, not asserted as human clinical kinetics.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"ss-ce-158 was among the more slowly dissociating modafinil analogues in the 2026 DAT-current-recovery experiments; plasma persistence and target residence are separate.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Optimizing cognitive enhancement through dopamine transporter modulation. | 2026 | DOI 10.1016/j.neuropharm.2026.110969 | PMID 41980668 | https://doi.org/10.1016/j.neuropharm.2026.110969","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 67-67; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"e0f5c128-dda8-5037-8a76-240d68560695","evidence_kind":"source_excerpt","locator":"Lines 67-67","start_line":67,"end_line":67,"excerpt":"**A 2026 update adds actual binding-kinetic experiments.** Investigators measured DAT-current recovery after inhibitor removal, compared R-modafinil with analogues, and studied dopamine dynamics and cognition in rats. More slowly dissociating analogues such as S-MK-26 and (S,S)-CE-158 performed better on selected outcomes, including tasks impaired by scopolamine. Brain exposure also differed. The findings support investigating residence time, but do not isolate it from every pharmacokinetic difference or show that marketed modafinil has no abuse liability. Findings from these analogues belong to their own records. [Niello et al., 2026](https://doi.org/10.1016/j.neuropharm.2026.110969)","model_system":"DAT-current recovery after inhibitor removal; transporter construct details remain in primary paper, not asserted as human clinical kinetics.","directness":"reported_statement","verification_status":"source_recorded","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"17a64928-eaa2-5117-ba4f-52dcbdf9cc9e","stable_key":"import-6660bba2-4fa0-590a-bf52-9803a24bea9f","title":"Modafinil: detailed mechanisms of action (reviewed 3 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"006008cb4cfd183dd3b0846d3abc66c8ebf40cf1b6bd1f0bcdb4f4d937a8e115","revision_id":"c85b3e2e-c18a-59fc-9e79-5c375e64d119","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}